United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $549.15, for a total value of $5,216,925.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,247,713.95. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $1.48 on Tuesday, reaching $548.09. The stock had a trading volume of 595,791 shares, compared to its average volume of 479,066. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The business’s 50-day moving average price is $566.45 and its 200 day moving average price is $522.10. The stock has a market cap of $23.27 billion, a P/E ratio of 20.23, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the firm posted $6.63 EPS. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Wellington Management Group LLP grew its holdings in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter worth $317,617,000. Norges Bank acquired a new position in United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC grew its holdings in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.